Clinical Trial Eligibility: Inclusion Criteria:

• Ages Eligible for Study: 18 Years - 75 Years,
• Genders Eligible for Study: Both
• Type 2 diabetes on diet and exercise therapy or monotherapy with metformin, insulin secretagogue, or alpha-glucosidase inhibitors, or a low-dose combination of these at ≤ 50% maximal dose (see Appendix). Dosing is stable for 8 weeks prior to randomization.

Clinical Trial Eligibility: Exclusion Criteria:

• Therapy with rosiglitazone (Avandia) or pioglitazone (Actos), or extendin-4 (Byetta), alone or in combination in the previous 6 months
• Use of weight loss drugs [e.g., Xenical (orlistat), Meridia (sibutramine), Acutrim (phenylpropanol-amine), or similar over-the-counter medications] within 3 months of screening or intentional weight loss of ≥ 10 lbs in the previous 6 months
• Use of warfarin (Coumadin), clopidogrel (Plavix) or other anticoagulants
• Use of probenecid (Benemid, Probalan), sulfinpyrazone (Anturane) or other uricosuric agents

Demographic Information

Medication:

• SDTM
• Drug Ontology
• Mapping Rule
• Intermediate Results

Apply Criteria

Drug Ingredient	Property

Apply Criteria

SDTM Query Sample
SDTM - HL7 Mapping Rule
Database - HL7 Mapping Rule
Drug Sub-Category Inclusion Rule
Weight Loss Drug Ingredient Inference Rule Used in Exclusion Criteria
RxNorm to NDC Code Conversion

Generated HL7 Query
Generated SQL Query